Histone Deacetylase Inhibitors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019
(PRWEB) July 22, 2014 -- Histone deacetylase (HDAC) are enzymes which remove acetyl groups from an N-acetyl lysine amino acid present on a histone, thus wrapping the DNA tightly by the histones. Histone deacetylase inhibitors (HDIs) are compounds which interfere with this function of histone deacetylase. HDIs display promising potential in oncology for applications such as diagnosis, cancer detection and prognosis. HDIs are emerging class of oncology therapeutics for the treatment of solid and hematological malignancies. Based on the classes, histone deacetylase are classified into class 1, class 2 and class 3 HDAC. HDAC inhibitors leads to accumulation of acetylated nuclear histones in both tumor and normal tissues, providing an alternate marker for the biological activity of HDAC inhibitors. Inhibition of HDAC also results in acetylation transcription factors such as GATA-1, p53 and estrogen receptor-alpha. HDIs are potent anti-proliferative agents with moderately little effect on normal tissues.
Get report sample PDF copy from here: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1927.
Based on applications, histone deacetylase inhibitors are categorized into oncology, neurology and others diseases. Presently there are four approved HDI products in the market namely Vorinostat (Zolinza), Romidepsin (Istodax), Vidaza and Dacogen. Consequently, global biopharmaceutical companies are conducting research for its application in different indications.
North America leads the histone deacetylase inhibitors market with rapid acceptance of these products in this region. Globally, this market would be growing at a very rapid pace owing to a tremendous potential of this class of drugs in oncology therapy. Rising incidence of oncology and aging population would be the driving factors for this market. Some of the key players in this market include Merck & Co., Inc., Celgene Corporation, Eisai Pharmaceuticals, Novartis, Acetylon Pharmaceuticals, Celleron Therapeutics, Envivo Pharmaceuticals and Pfizer, Inc. These companies are aiming to discover new products in this class, through prospective pipeline, collaborations and ventures.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include:
- North America
- Asia Pacific
- Europe
- Rest of the World
Request for customization of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1927.
This report provides comprehensive analysis of:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying This Report:
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a technological growth map over time to understand the industry growth rate
- It provides a seven-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
More reports on: https://www.linkedin.com/today/author/73190868.
Sheela AK, Transparency Market Research, http://www.transparencymarketresearch.com, +1 518-618-1030, [email protected]
Share this article